Gujarat Kidney And Super Speciality Limited
All news and filings related to Gujarat Kidney And Super Speciality Limited.
View all news & filings- Low impact
Gujarat Kidney And Super Speciality Limited announces 7th AGM with e-voting
Gujarat Kidney And Super Speciality Limited has dispatched its annual report for 2025-26, including the notice for the 7th AGM and e-voting procedures. This was published in 'Gujaratmitra' and 'Gujaratdarpan' on September 4, 2026, in compliance with SEBI regulations.
Read the summary - Medium impact
Gujarat Kidney And Super Speciality Limited Announces 7th AGM on Sep 28, 2026
Gujarat Kidney And Super Speciality Limited will hold its 7th AGM on September 28, 2026. The agenda includes adopting FY26 financial statements, appointing directors, approving secretarial auditors, and revising remuneration for MD (₹18L to ₹36L) and Whole-time Director (₹18L to ₹24L). Members will also vote on borrowing powers up to ₹500 Cr.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Ltd. Announces 7th AGM on Sep 28, 2026
Gujarat Kidney And Super Speciality Limited will hold its 7th Annual General Meeting (AGM) on September 28, 2026. The notice of the AGM was published in newspapers on September 1, 2026, and will be available on the company's website.
Read the summary - Low impact
Gujarat Kidney and Super Speciality Limited to Participate in GIA Healthcare Day on August 31, 2026
Gujarat Kidney And Super Speciality Limited will attend the GIA Healthcare Day on August 31, 2026, in Mumbai. This investor and analyst meet is a physical group meeting from 10:00 AM to 11:00 AM. The company will use publicly available information and no UPSI will be discussed.
Read the summary - Low impact
Gujarat Kidney Appoints Disha Bharpoda as Additional Non-Executive Independent Director
Gujarat Kidney And Super Speciality Limited appointed Mrs. Disha Bharpoda as Additional Non-Executive Independent Director effective August 24, 2026. Shareholders previously approved a variation in IPO proceeds utilization via postal ballot.
Read the summary - Low impact
GKSL Appoints Mrs. Disha Bharpoda as Additional Non-Executive Independent Director
Gujarat Kidney And Super Speciality Limited appointed Mrs. Disha Bharpoda as Additional Non-Executive Independent Director on August 24, 2026. Her appointment is for five years, pending shareholder approval. Mrs. Bharpoda has an MD in Radiology and prior medical experience.
Read the summary - Low impact
Gujarat Kidney Appoints Mrs. Disha Bharpoda as Additional Non-Executive Independent Director
Gujarat Kidney And Super Speciality Limited appointed Mrs. Disha Bharpoda as an Additional Non-Executive Independent Director on August 24, 2026. Her appointment is for five years and requires shareholder approval. She holds an MD in Radiology and has prior medical experience.
Read the summary - Low impact
GKSL Q1 FY27 Un-Audited Financial Results Reviewed by Auditors
Gujarat Kidney And Super Speciality Limited's Q1 FY27 un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, have undergone a limited review by independent auditors. The auditors found no material misstatements in the financial statements.
Read the summary - Low impact
GKSL Q1 FY27 Un-Audited Financial Results Reviewed
Gujarat Kidney And Superspeciality Limited announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The results have been reviewed by independent auditors and taken on record by the Board of Directors.
Read the summary - Medium impact
Gujarat Kidney Appoints Paresh Dhoti as Additional Non-Executive Independent Director
Gujarat Kidney And Superspeciality Limited appointed Mr. Paresh Dhoti as Additional Non-Executive Independent Director. This appointment is for a five-year term, subject to member approval at the upcoming AGM. Mr. Dhoti previously served as a Non-Executive Non-Independent Director.
Read the summary - Low impact
GKSL Monitoring Agency Report: Funds Utilized as per SEBI Norms for Q4FY26
Gujarat Kidney and Super Speciality Limited's Q4FY26 Monitoring Agency Report confirms utilization of ₹250.80 Crore IPO funds. No deviations from objects were noted. Funds were used for acquisitions, capital expenditure, and debt repayment. Unutilized funds remain in bank accounts and fixed deposits.
Read the summary - Low impact
GKSL clarifies discrepancies in financial results submission and XBRL data
GKSL clarifies discrepancies in financial results submission to NSE. The company addressed a delay in submission by stating a penalty was paid. Regarding XBRL discrepancies, GKSL resubmitted corrected standalone and consolidated cash flow statements, attributing the errors to inadvertent data entry.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited Publishes Postal Ballot Notice in Newspapers
Gujarat Kidney And Super Speciality Limited has published its Notice of Postal Ballot in The Financial Express and Gujarat Mitra on July 23, 2026. This action is in compliance with SEBI Listing Obligations and Disclosure Requirements.
Read the summary - Low impact
GKSL Appoints Paresh Dhoti as Non-Executive Non Independent Director
Gujarat Kidney And Super Speciality Limited appointed Mr. Paresh Dhoti as Additional Non-Executive Non Independent Director on 09.07.2026. The company intends to consider him for the Non-Executive Independent Director role in a future board meeting.
Read the summary - Low impact
GKSL Corrects Typographical Error in Standalone Financial Statements Signing Date
GKSL clarifies a typographical error in the signing date of its Standalone Financial Statements. The correct signing date was May 28, 2025. The company will upload corrected statements online and assures no impact on financial figures.
Read the summary - Low impact
GKSL Submits SEBI Reg 74(5) Certificate for Dematerialised Shares
Gujarat Kidney And Super Speciality Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018. The certificate, received from the Registrar and Share Transfer Agent, details shares dematerialised during the quarter ended June 30, 2026.
Read the summary - High impact
GKSL to acquire 51% stake in UAE's Blue Tree Clinics LLC for ₹19.84 Crore
GKSL will acquire a 51% stake in UAE's Blue Tree Clinics LLC for ₹19.84 Crore. The company also appointed Mr. Paresh Dhoti as Additional Non-Executive Independent Director. A postal ballot will be held for shareholders to approve variations in IPO objects.
Read the summary - High impact
GKSL Acquires 51% Stake in UAE's Blue Tree Clinics for ₹19.84 Crore; Appoints New Director
Gujarat Kidney And Super Speciality Limited will acquire a 51% stake in UAE-based Blue Tree Clinics LLC for ₹19.84 crore. The acquisition is expected to be completed within 50 days. The company also appointed Mr. (Dr) Paresh Dhoti as an Additional Non-Executive Independent Director.
Read the summary - Medium impact
GKSL Shareholders Approve Variation in IPO Proceeds Utilization via Postal Ballot
GKSL shareholders approved a special resolution to vary the utilization of IPO proceeds via postal ballot. The voting concluded on July 4, 2026, with an overwhelming 99.9995% of polled votes in favor. The decision signifies strong shareholder confidence in the company's revised financial strategy.
Read the summary - Medium impact
GKSL seeks shareholder approval for variation in IPO proceeds utilization
Gujarat Kidney And Super Speciality Limited (GKSL) is seeking shareholder approval via postal ballot for a variation in IPO proceeds utilization. The e-voting period is from June 5 to July 4, 2026. Funds will be reallocated for expansion in an existing subsidiary and inorganic growth.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited Publishes Notice of Postal Ballot in Newspapers
Gujarat Kidney And Super Speciality Limited has published a notice of Postal Ballot in The Financial Express and Gujarat Mitra on June 4, 2026. This action is in compliance with SEBI Listing Regulations.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited Publishes Audited Financial Results
Gujarat Kidney And Super Speciality Limited published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results were published in Free Press (English) and Lokmitra (Gujarat) on May 29, 2026, in compliance with SEBI regulations.
Read the summary - Medium impact
GKSL Board Approves FY26 Financial Results, Appoints Auditors
GKSL's Board approved FY26 audited standalone and consolidated financial results ending March 31, 2026. Mr. Siddharth Atulbhai Shah appointed Internal Auditor for FY27. SPANJ & Associates appointed Secretarial Auditor for five years, subject to shareholder approval.
Read the summary - Medium impact
Gujarat Kidney Approves FY26 Results, Appoints Secretarial Auditor
Gujarat Kidney And Super Speciality Limited's Board approved FY26 audited standalone and consolidated financial results. The company appointed Mr. Siddharth Atulbhai Shah as Internal Auditor for FY27 and SPANJ & Associates as Secretarial Auditors for five years, subject to member approval.
Read the summary - Medium impact
GKSL Board Approves FY26 Financial Results, Appoints Internal and Secretarial Auditors
GKSL's Board approved audited standalone and consolidated financial results for FY26, ending March 31, 2026. Mr. Siddharth Atulbhai Shah was appointed Internal Auditor for FY27. SPANJ & Associates appointed as Secretarial Auditor for five years, subject to member approval.
Read the summary - Low impact
GKSL Q4FY26 Monitoring Report: ₹250.80 Crore IPO Proceeds Utilized as per Plan
Gujarat Kidney and Super Speciality Limited's Q4FY26 monitoring report confirms ₹250.80 Crore IPO proceeds were utilized as per the offer document. Key uses include hospital acquisition, subsidiary stake purchase, capex, and debt repayment. Unutilized funds stand at ₹13.04 Crore. The report by Brickwork Ratings indicates no deviations in fund utilization.
Read the summary - High impact
GKSL to Deploy 100 AI-Enabled Haemodialysis Machines Across Network
GKSL is procuring 100 AI-enabled Haemodialysis machines to scale its renal care services. The first 8 machines will be deployed at its Gujarat Multi Specialty Hospital in Godhra within 10 days. This strategic expansion aims to enhance patient care and increase dialysis capacity across Gujarat.
Read the summary - Medium impact
Gujarat Kidney Appoints New Company Secretary; Approves Wholly Owned Subsidiary
Gujarat Kidney And Super Speciality Limited appointed Ms. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer. The Board also approved the incorporation of a Wholly Owned Subsidiary to expand healthcare services in Bharuch, Gujarat. This WOS is expected to be incorporated by the end of H1 FY26-27 with an initial capital of ₹1,00,000.
Read the summary - Medium impact
GKSL Appoints Ms. Vishakha Phadke as Company Secretary; Approves Wholly Owned Subsidiary
GKSL appointed Ms. Vishakha Phadke as Company Secretary & Compliance Officer on April 27, 2026. The board also approved the incorporation of a Wholly Owned Subsidiary to expand healthcare services in Bharuch, Gujarat. Shareholders previously approved this via postal ballot on April 25, 2026. WOS incorporation is expected by H1 FY26-27.
Read the summary - Medium impact
GKSL Shareholders Approve Healthcare Expansion, Financial Statement Revision, and Secretarial Auditor Appointment
GKSL shareholders approved key resolutions via postal ballot, including funds for healthcare expansion and revision of financial statements. Mr. Dharmendra Bhaliya was appointed as Secretarial Auditor for FY 2025-26. All resolutions passed with the required majority.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited Announces General Updates
Gujarat Kidney And Super Speciality Limited has released general updates concerning its operational activities and strategic plans. The company is focused on improving services and expanding its market reach. More details will be shared in future announcements.
Read the summary - Low impact
GKSL Fined ₹10,000 Each by NSE & BSE for Delayed Board Meeting Intimation
Gujarat Kidney And Super Speciality Limited (GKSL) was fined ₹10,000 each by NSE and BSE for delayed board meeting intimation. The company will pay the fines within the stipulated timelines. No impact on financial or operational activities is expected.
Read the summary - Low impact
Gujarat Kidney And Superspeciality Limited Submits SEBI Compliance Certificate
Gujarat Kidney And Superspeciality Limited submitted a SEBI compliance certificate for the quarter ended March 31, 2026. The certificate confirms all shares are in electronic form, with no physical holdings. The submission was made on April 7, 2026.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited Closes Trading Window from April 1, 2026
Gujarat Kidney And Super Speciality Limited will close its trading window from April 1, 2026. This is in compliance with SEBI's insider trading regulations. The window will reopen 48 hours after the declaration of audited financial results for the year ended March 31, 2026.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited Dispatches Postal Ballot Notice
Gujarat Kidney And Super Speciality Limited has dispatched its Postal Ballot Notice dated March 25, 2026, to its members. E-voting is open from March 27, 2026, to April 25, 2026. Results will be announced within seven days post-scrutiny.
Read the summary - Medium impact
GKSL Announces Postal Ballot for E-Voting on Fund Utilization and Financial Statement Revision
Gujarat Kidney And Superspeciality Limited is conducting a postal ballot via remote e-voting from March 27 to April 25, 2026. Shareholders will vote on the utilization of IPO funds for healthcare expansion, including potential acquisitions and capital expenditures. They will also vote on revising financial statements for the past three years and appointing a secretarial auditor.
Read the summary - Medium impact
Gujarat Kidney Q2 FY26 Standalone Profit After Tax Rs 230.12 Lacs
Gujarat Kidney And Super Speciality Limited reported standalone Profit After Tax of ₹230.12 Lacs for Q2 FY26, down from ₹389.98 Lacs in Q2 FY25. Revenue from operations decreased to ₹964.26 Lacs from ₹1,144.99 Lacs year-on-year. Consolidated PAT for H1 FY26 was ₹827.96 Lacs.
Read the summary - Medium impact
GKSL Acquires Parekhs Hospital Pvt. Ltd. for ₹77 Crore to Expand Healthcare Presence
Gujarat Kidney And Superspeciality Limited acquired Parekhs Hospital Private Limited for ₹77 crore. This acquisition aims to strengthen GKSL's healthcare sector presence and diversify its business. Parekhs Hospital reported a turnover of ₹25.67 crore in FY25.
Read the summary - Low impact
Gujarat Kidney Fined ₹6.6 Lakh by NSE & BSE for Delayed Financial Results
Gujarat Kidney And Superspeciality Limited was fined ₹3,30,400 by both NSE and BSE for delayed submission of financial results. The total penalty amounts to ₹6,60,800. The company has already paid the fines.
Read the summary - Low impact
Gujarat Kidney Appoints Secretarial & Internal Auditors for FY26
Gujarat Kidney And Super Speciality Limited appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY25-26. These decisions were made during a Board meeting on March 19, 2026.
Read the summary - Medium impact
Gujarat Kidney And Super Speciality Appoints Secretarial & Internal Auditors for FY26
Gujarat Kidney And Super Speciality Limited appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY26. The company reported Q2 FY26 standalone net profit of ₹2.30 crore and half-yearly profit of ₹6.20 crore. Consolidated Q2 FY26 net profit was ₹2.32 crore.
Read the summary - Medium impact
Gujarat Kidney And Super Speciality Appoints Secretarial and Internal Auditors for FY26; Reports Q2 Results
Gujarat Kidney And Super Speciality Limited appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY26. The company reported standalone Q2 FY26 revenue of ₹964.26 lacs and profit after tax of ₹230.12 lacs. Consolidated Q2 FY26 revenue was ₹1,144.99 lacs with profit after tax of ₹389.98 lacs.
Read the summary - Low impact
GKSL Fined ₹6.6 Lakhs by NSE & BSE for Delayed Financial Results
Gujarat Kidney And Superspeciality Limited (GKSL) has been fined ₹6,60,800 (₹3.3 Lakhs per exchange) by NSE and BSE for not submitting financial results for the quarter ended September 30, 2025, on time. The company received the notices on March 17, 2026, and stated no operational impact.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited: Delay in Q2 FY26 Financial Results Submission
Gujarat Kidney And Super Speciality Limited reported a delay in submitting its Q2 FY26 financial results due to technical issues. The company listed on December 30, 2025. Standalone Q2 revenue was ₹964.26 lacs, with profit after tax at ₹230.12 lacs. Consolidated Q2 revenue stood at ₹1,292.88 lacs, with profit after tax at ₹287.64 lacs.
Read the summary - Low impact
Gujarat Kidney And Super Speciality: Company Secretary & Compliance Officer Resigns
Mrs. Niki Paresh Tiwari has resigned as Company Secretary and Compliance Officer of Gujarat Kidney And Super Speciality Limited. Her last day of employment will be March 27, 2026. The company is actively searching for a replacement.
Read the summary - Low impact
GKSL Reports No Deviation in Public Issue Fund Utilization for Q3 FY26
Gujarat Kidney And Super Speciality Limited confirms no deviation in the utilization of ₹2,508,000,000 raised from its public issue for the quarter ended December 31, 2025. Funds were allocated to acquisitions, capital expenditure, and debt repayment.
Read the summary - Low impact
Gujarat Kidney And Super Speciality Limited IPO Fund Utilisation Report Q3 FY26
Gujarat Kidney And Super Speciality Limited's IPO fund utilisation report for Q3 FY26 shows ₹250.80 Crore raised. As of December 31, 2025, ₹193.05 Crore remains unutilised across various objectives including hospital acquisitions and capex. ₹50.04 Crore was used for general corporate purposes.
Read the summary - Low impact
Gujarat Kidney Allowed to Revise Financial Statements for FY22-24
Gujarat Kidney And Super Speciality Limited received NCLT approval to revise its Board's Reports and financial statement notes for FY22, FY23, and FY24 due to clerical errors. The company must pay ₹10,000 and file revised forms within 30 days.
Read the summary - Medium impact
GKSL Q3FY26 Results: Standalone Profit ₹233.26 Lakhs, Consolidated Profit ₹370.62 Lakhs
Gujarat Kidney and Super Speciality Limited approved standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Standalone profit after tax for Q3FY26 was ₹233.26 Lakhs, and for nine months was ₹853.36 Lakhs. Consolidated profit after tax for Q3FY26 was ₹370.62 Lakhs, and for nine months was ₹1,198.58 Lakhs.
Read the summary - Medium impact
GKSL Acquires 51% Stake in Patel Pharmacy & Patel Multispeciality Hospital for ₹12.5 Crore
Gujarat Kidney And Superspeciality Limited acquired 51% stakes in Patel Pharmacy for ₹3.70 crore and Patel Multispeciality Hospital and ICU for ₹8.80 crore. The total investment amounts to ₹12.50 crore. Both acquisitions are expected to strengthen GKSL's presence and diversify its business portfolio in the healthcare sector.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio